anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject liniment having stable foam retentivity, excellent in use feeling, safe to the human body and the environment, by filling a specific foamer container with a specified liquid composition having a sodium ion in an amount not more than a specific amount. SOLUTION: The objective liniment is obtained by filling a foamer container having a porous membrane with a liquid composition comprising (A) a fluorinated compound capable of supplying 0.5-2 wt.% fluorinated material ion (e.g. sodium fluoride), (B) a phosphorylated material capable of providing 0.01-10 wt.% phosphate ion (e.g. tripotassium phosphate), (C) 1.0-5.0 wt.% anionic surfactant (e.g. sodium laurylsulfate) and (D) 0.1-10.0 wt.% nonionic surfactant (e.g. a polyoxyethylene-polyoxypropylene copolymer), and containing &lt;=2 wt.% sodium ion in the whole components, so as to form a foamy state when ejected from the container.
The invention relates to a traditional Chinese medicine composition used for treating acnes. In modern times, people&#39;s daily diet has undergone enormous changes with increasingly accelerated life rhythms, and people&#39;s working rhythms are also accelerated. A flood of fast foods, entertainments and parties cause great harm to people&#39;s bodies, and especially to endocrine of females. The great harm is shown on faces. More and more females suffer from acnes. Generally, various whitening products in the market can not provide a treatment effect, but provide layers of coverings on the faces. The whitening products provide only temporary solutions, but the root causes are not treated.
PURPOSE:To obtain the composition for dyeing the hair, capable of gradually dyeing the hair. CONSTITUTION:A composition for dyeing hair contains hematoxylin of formula I, a color generation-retarding agent and a metal compound. A composition for dyeing hair contains brazilin of formula II, a color generation-retarding agent and a metal compound. The color generation-retarding agent includes a reducing agent (e.g. ascorbic acid) and a chelating agent (e.g. ethylenediamine tetraacetate), and the metal compound includes the oxides, hydroxides, sulfates, and hydrochlorides of Fe, Sn, Cr, Co, Ni and Mn. When the reducing agent is used as the color generation-retarding agent, a metal compound of low atomic valency state us used. A compound of formula III (R&lt;1&gt;, R&lt;2&gt;, R&lt;4&gt;, R&lt;7&gt; are H, OH, alkyloxy) which is a compound similar to the hematoxylin and the brazilin can also be used as a component composing the composition. The composition is preferably used for a hair-dyeing treatment wherein the color is generated approximately a half day or a day later after the application of the composition to a hair-generating site, etc.
A shelf-stable device for transdermally administering an active  pharmaceutical  to  a patient.   The  device  includes  a  drug reservoir  that  contains  the  drug  formulation.   In  one  preferred embodiment of the present invention, the drug reservoir is sandwiched between an upper and a lower solvent barrier film that are made from a material such as a polyester that will not absorb the drug and/or skin  permeating  enhancing  solvent,  if any,  contained  within  the reservoir.   The  drug  reservoir  and  solvent  barrier  films  are encapsulated within a hermetically-sealed compartment that protects the drug formulation from common environmental factors such as water vapor, oxygen, and light which can adversely affect the stability and efficacy   of   the   drug   formulation.    The   hermetically-sealed compartment  also  prevents  the  drug  formulation  from  coming  into contact with and possibly dissolving the adhesive used to secure the device to the patient&#39;s  skin.   In  another particularly  preferred embodiment of the present invention, the device&#39;s drug reservoir is encapsulated within a hermetically-sealed compartment that is made from solvent/environment barrier films that serve the dual functions of preventing the device&#39;s components from absorbing the drug/solvent formulation  from  the  reservoir,  and  protecting  the  drug/solvent formulation from common environmental factors.
One aspect of this invention is directed to a pharmacologically acceptable composition including a sulfate of 3 alpha, 7 beta-dihydroxy-5 beta-cholan-24-oic acid (Ursodeoxycholic acid or &#34;UDCA&#34;) and a pharmacologically acceptable carrier. In a preferred composition, the sulfate is UDCA-3-sulfate, UDCA-7-sulfate, UDCA-3,7-disulfate, glyco-UDCA-3-sulfate, glyco-UDCA-7-sulfate, glyco-UDCA-3,7-disulfate, tauro-UDCA-3-sulfate, tauro-UDCA-7-sulfate, tauro-UDCA-3,7-disulfate or a combination thereof. Another aspect of the invention concerns a method of delivering UDCA to a mammal to inhibit or treat a disorder, which includes administering a sulfate of UDCA to the mammal in an amount sufficient to inhibit or treat the disorder. For example, a UDCA sulfate may be used to advantage in inhibiting or treating an inflammatory condition of the gastrointestinal tract, such as colon cancer, rectum cancer, a neoplasm of the colon, a neoplasm of the rectum, carcinogenesis of the colon, carcinogenesis of the rectum, ulcerative colitis, an adenomatous polyp, familial polyposis and the like. A sulfate of UDCA also may be administered to inhibit or treat an inflammatory disorder of the liver. A UDCA sulfate may be used to improve serum biochemistries of liver disease or liver function, to increase bile flow or to decrease biliary secretion of phospholipid or cholesterol. In yet a further aspect, the invention is directed to a method of maintaining an isolated organ by perfusing the organ with a sulfate of UDCA.
In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients&#39; tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.
The invention relates to a system for monitoring a patient&#39;s physiological signals and associated devices. Signals are transmitted wirelessly between the battery powered data acquisition subsystem (which also stores the data for later transmission if the wireless link is unavailable) and the host system which has a standard Microsoft Windows Graphical User Interface. The system also allows transmission of control signals from the host system to the data acquisition sub-system. Bluetooth technology, utilised for the digital transmission and encryption of data, will also form the foundation for the automatic detection of host proposed for the system. It has application in ambulatory or static studies in hospitals, clinics or elsewhere, providing wireless connectivity of medical devices allowing systems to be configured and located to suit patients and care staff. Embodiments detail a urine flowmeter, a urodynamics system, a gastro-intestinal motility system and an ano-rectal manometry system.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition, a formulation, a method, and a system for treating thyroid eye disease and related conditions (e.g., Grave&#39;s ophthalmopathy).  &lt;P&gt;SOLUTION: The method includes a step of administering, to a patient in need, a systemic or local β adrenergic agonist (e.g., as an extended release crystalline micro particle suspension). The method can further include administering a compound for reducing β adrenergic receptor desensitization (e.g., a corticosteroid) prior to administeration or coadministeration of the β adrenergic agonist. The method can also include locally administering to the eye an immuno suppressant agent (e.g., rapamycin) prior to administering a β adrenergic agonist. The composition described in the specification includes ophthalmic pharmaceutical formulations of β adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with β adrenergic agonist solutions. The composition also includes ophthalmic formulation of a compound for reducing β adrenergic receptor desensitization in the form of extended release crystalline microparticle suspensions.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To produce the subject compound exhibiting an antiulcer activity with industrial advantage by developing rice malt in rice using a rice Aspergillus belonging to Ustilaginoidea and exhibiting an ustilogicin A or B productivity and subsequently isolating the product from the rice malt. CONSTITUTION:A rice molt is developed in rice using an ustilogicin A- or ustilogicin B-producing rice Aspergillus [e.g. Ustilaginoidea virens Cooke SANK 15391 strain (Bikoken stipulation No. 3691)] belonging to Ustilaginoidea and the produced rice molt is then collected and dried. The dried material is subsequently crushed together with water in a mixer and then subjected to shaking extraction at room temperatures for 1hr. The resultant extract is filtered and the obtained filtrate is concentrated. The concentrated solution is fractionated and purified by adsorption column chromatography, high-performance liquid chromatography, etc., thus producing the objective new compound, ustilogicin A or ustilogicin B represented by the formula (R&lt;1&gt; is H or a 1 to 5C alkyl; R&lt;2&gt; is H or a 2 to 6C aliphatic acyl; R&lt;3&gt; is methyl or propyl) and exhibiting an antiulcer activity.
NEW MATERIAL:A compound shown by formula I (R&lt;1&gt; to R&lt;3&gt; are H or alkyl). USE:Useful as a drug, an agricultural chemical and a reagent for preparing pathologic model of stiff-man syndrome. PREPARATION:For example, an amine compound is obtained by reductive amination reaction between a lactol derivative derived from 2-indane and vinylglycinol derivative derived from L-methionine. Then the amino compound is subjected to N-protection with tert. butoxycarbonyl to give an aldehyde derivative shown by formula II. Then this compound is reacted by light irradiation, selectively oxidized to give a ketone derivative shown by formula III. Further, the ketone derivative is treated by oxidation of methanol into carboxylic acid and esterification with diazomethane. Then the resulting substance is oxidized and cleft and hydrolyzed to give a dicarboxylic acid shown by formula IV, which is reduced to give a compound shown by formula V.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a dental plaque stain which effectively stains dental plaque to make it sufficiently visually recognizable, scarcely stains parts other than the dental plaque or is amenable to destaining by brushing, and is effective for use in a dental stain liquid for inspection.  &lt;P&gt;SOLUTION: The first dental plaque stain contains Monascus Yellow, and the second dental plaque stain contains at least one member selected from among Monascus Yellow, Gardenia Yellow, and Red radish color. These stains can stain dental plaque to form stained plaque which can be easily destained by e.g., brushing. The visual recognizability of stained plaque can be improved by adding a red tar pigment to the dental plaque stain containing Monascus Yellow. The third dental plaque stain containing a red tar pigment and a turmeric (Curcuma longa) extract and/or curcumin can selectively stain dental plaque to give stained dental plaque having visual recognizabiliy better than that of plaque stained with a turmeric extract or curcumin alone.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of easily manufacturing a supermolecule nano-assembly at room temperature without using a synthetic ligand and a template and a supermolecule nano-assembly.  &lt;P&gt;SOLUTION: This supermolecule nano-assembly is manufactured by the method having a step of mixing a transition metallic salt and nucleotide in water at room temperature. The transition metallic ions and nucleotide voluntarily form a supermolecule nano-assembly by self-organization. When a rare-earth salt is used as a transition metallic salt, a rare-earth nano-particle having strong fluorescent light emission and high magnetic moment can be provided. When a silver salt is used as a transition metallic salt, a nano-fiber is provided. When the concentration of a silver salt and nucleotide is increased, a hydrogel is generated.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention discloses an oral-administration medicine treating anal cryptitis, and belongs to the technical field of medicines. The oral-administration medicine employs fruit of hibiscus syriacus L., rhizome of thinnest yam, flower of blue plantainlily, berberis atrocarpa Schneid., fortune firethorn fruit, cinnamomum glanduliferum, primula forbesii franch., saussurea nigrescens Maxim., naoyu millettia, fig leaf, castanopsis chinensis hance leaf, all-grass of Clark&#39;s blumea, flower of shrubby woodfordia, root-bark of red nanmu, burmann cinnamon bark, flower or root of lightyellow snapweed, diclofenac sodium, cyclodextrin, a glycyrrhizic acid medicament, sodium citrate, 4-acetamidophenol, polyvinylpyrrolidone and salicylic acid as effective compositions. The medicine carefully employs multiple traditional Chinese medicine compositions, possesses the efficacies of clearing heat and expelling toxin, dispelling wind and eliminating dampness, activating blood and cooling blood, warming the middle and guiding qi downward, promoting urination and checking diarrhea, and is capable of expelling organ toxin. The western medicine compositions are capable of rapidly diminishing inflammation, easing pain, relieving fever, and adjusting body immunity. The prescription is strict and reasonable for compatibility, the western medicine compositions can make up the insufficiency of the traditional Chinese medicine compositions, and the traditional Chinese medicine compositions can neutralize the side effects of the western medicine compositions, combination of the western medicine compositions and the traditional Chinese medicine compositions helps to radically treat the disease. The medicine is definite in curative effect, fast in effectiveness and high in cure rate.
The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200  mu g/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants constitutes at least 35% (w/w) of the total protein; or to compositions comprising at least 400  mu g/ml mannan binding lectin (MBL) and/or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and/or MBL variants and divalent cations. The invention also describes methods of preparing said compositions. &lt;??&gt;The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an external preparation for skin capable of providing sufficient viscosity by a simple operation and excellent in feelings upon use in a salt type agent formulation system.  &lt;P&gt;SOLUTION: The external preparation for skin is obtained by formulating a salt type agent with xanthan gum and guar gum. It is preferable for the external preparation that the weight ratio of the xanthan gum to the guar gum is (10:90) to (90:10), further (20:80) to (80:20). The external preparation for skin is excellent in viscosity stability at high temperature when the weight ratio is particularly (50:50) to (20:80). The salt type agent is preferably an ascorbic acid-based and/or alkoxysalicylic acid-based bleaching agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A preparation method of Nostoc commune ethanoic extract capable of inhibiting fat accumulation and reducing body fat includes: drying and grinding fresh Nostoc commune to be Nostoc commune powder, and using 95% ethanol to extract the Nostoc commune powder so as to obtain the Nostoc commune ethanoic extract. The Nostoc commune ethanoic extract with the concentration of 1~50&lt;mu&gt;g /mL is used to be a raw material of Nostoc commune healthy food, or a feed additive or a food product, so as to inhibit adipocyte proliferation and lipid accumulation. In addition, the Nostoc commune ethanoic extract can be further extracted to purify the raw materials of Nostoc commune polysaccharides and triterpenes. Thereby, by the Nostoc commune ethanoic extract having different antioxidant abilities and containing phytochemicals of being beneficial to human body, the effect of lowering pre-adipocyte proliferation and body fat can be observered in the 3T3-L1 cell culturing mode. Moreover, the noodle with 2% Nostoc commune has good consumer acceptance. After colding and dressing with sauce or performing a boiled cooking, the Nostoc commune in the noodle can not only inhibit triglycerides accumulation in adipocytes, but also reduce 3T3-L1 preadipocyte proliferation so as to achieve the effect of reducing adipocyte formation.
It has been discovered that proliferation of inflammatory breast cancer (IBC) cells can be inhibited by inhibiting the function of histone deacetylase 6 (HDAC6). Advantageously, such functional inhibition is accomplished by administration of a therapeutically effective dose of Ricolinostat (ACY1215) to a patient in whom IBC cells are proliferating. In further accordance with the invention, it is possible to predict the responsiveness of a particular patient with cancer (particularly breast cancer, and most specifically inflammatory breast cancer) to administration of an HDSC6 inhibitor. This is accomplished by acquiring mRNA gene expression profiles of a biopsy sample of the patient&#39;s tumor tissue. The processed gene expression profiles of the patient are then integrated into a gene expression database and are then normalized across the entire database. Then, the normalized gene expression profiles are input to an algorithm. An HDAC6 signature characteristic of the patient&#39;s tumor type is also input to the algorithm, and the output of the algorithm makes it possible to evaluate the responsiveness of the patient&#39;s tumor to administration of HDAC6 inhibitor. Advantageously, the gene expression profiles are acquired using standard RNA-Seq technology or microarray and the gene expression database is The Cancer Genome Atlas (&#34;TCGA&#34;).
The present invention relates to an application compliance device (1) for monitoring a customized dosage regime of a skin care product provided in a container device (20). The device comprises a housing (2) having an inner wall (2a) and an outer wall (2b), and defining a top opening (2c) with a first diameter (D1) for receiving the container device (20) in the application compliance device (1). The device further comprises a control unit (8), a sensor unit (10) configured to sense a quantity of the skin care product administered from the container device (20), when being received in the application compliance device (1), and a signal unit (7). The sensor unit (10) and the signal unit (7) are coupled to the control unit (8). The housing (2) houses the control unit (8), the sensor unit (10) and the signal unit (7). The control unit (8) is configured to evaluate a quantity signal received from the sensor unit (10) to determine an administered dosage quantity, to control the signal unit (7) to generate a compliant signal if the administered dosage quantity is compliant with the customized dosage regime, to control the signal unit (7) to generate a partly compliant signal if the administered dosage quantity is not compliant with the dosage regime for a first time, and to control the signal unit (7) to generate a warning signal if the administered dosage quantity is not compliant with the dosage regime for a second time. The invention also relates to a method of monitoring such a customized dosage regime and to methods for determining a therapy surface on a patient&#39;s skin.
Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC&#39;s.
FIELD: medicine, narcology, pharmacy. SUBSTANCE: invention relates to agents producing the sobering effect. Invention proposes an agent declining toxic effect of alcohol and method for its preparing. Agent represents phytocomposition comprising grape crests an aqueous-spirituous extract, Saint-John&#39;s-wort herb and wild rose whole fruits an aqueous-spirituous extract. Method for preparing involves extraction of mixture of milled grape crests, Saint-John&#39;s-wort herb and whole wild rose fruits with an aqueous-spirituous extractant taken in the ratio = 2:1:1, respectively. Agent prepared by this procedure provides elimination of the enhanced intoxicating effect of alcohol. EFFECT: valuable medicinal properties of agent. 9 cl, 4 tbl, 3 ex
The present invention discloses a medicinal plaster for treating sinew and bone soft tissue injury pain, bone fractures and dislocation, which is mainly prepared from raw material ingredients of the following composition percent by weight: 140 to 160 parts of Chinese angelica root, 110 to 130 parts of safflower, 140 to 160 parts of olibanum, 140 to 160 parts of myrrh, 140 to 160 parts of radix et rhizoma rhei from Sichuan of china, 90 to 110 parts of dragon&#39;s blood and 140 to 160 parts of notoginseng. The present invention has the effects of promoting blood flow, eliminating swelling, quickly arresting bleeding, quickly killing pain, fast reuniting sinews and bones, reducing infections and complications and promoting the healing of bone fracture tissue. The time of the healing of bone fractures is short, the course of treatment is shortened, porosis is fast, and the recovery of neurological functions is quick. The medicinal plaster is used for treating more than one thousand of patients with various bone fractures by far, and the bone fractures of the patients are all healed, wherein the time of the healing of fresh fractures of teenagers is half of the natural healing time in clinic, and the time for senile patients with bone fractures can be shortened by one third. Various old fractures can be healed through pertinent adjustment, antibacterium treatment, and external application of the medicinal plaster. The present invention has the advantages of rich and easily-acquired raw materials, simple processing, simple operation and easy acceptance of treatment by patients.